万古霉素与替考拉宁治疗肝移植术后MRSA菌血症疗效与安全性比较

目的：比较万古霉素和替考拉宁治疗重症监护病房肝移植术后耐甲氧西林金黄色葡萄球（MRSA）感染的疗效和安全性。方法：将12例肝移植术后MRSA感染病人随机分为万古霉素治疗组和替考拉宁治疗组，比较两组病人应用抗生素后的治愈率和不良反应。结果：万古霉素与替考拉宁治疗MRSA的治愈率分别为71．4％和60．0％，细菌清除率分别为88．2％和86．7％，不良反应发生率为28．5％和60％，两组间MRSA治愈率有显著性差异（P〈0．05）。结论：万古霉素对重症监护病房肝移植术后MRSA感染的早期治疗效果优于替考拉宁，可以作为此类病人的首选用药。

Evaluation of Vancomycin and Teicoplanin in the Treatment of Infection Caused by Methicillin-resistant Staphylococcus aureus in Intensive Care Unit

Objective： To compare the effectiveness and safety of vaneomycin and teicoplanin in tile treatment of methieillin-resistant Staphylococcus aureus （MRSA） infection ira palient received liver-transpahrt operation in lhe iutensive care unit （ICU）. Methods： Twelve patients with MRSA infection were randomly divided into vaneomyein group and teieoplanin group. Results： For tire groups of vancomyein and teivoplanin, the total clinical effeeliw rates were 71.4% and 60.0% （P〈0.05）; lhe bacteria clear rates were 88.2% and 86.7%; and the incidence of side effects were 28.5% and 60%, respectively. Conclusion： Vancoycin is more effective in Ihe treatment of liver-transplanted patients with MRSA infeclion in ICL than leicoplanin, and can be used for these patients as preferred medication.